Fiona Blackhall
The Christie NHS Foundation Trust · The Christie NHS Foundation Trust Clinical Trials Unit; UK
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Fiona Blackhall as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 08:07 UTC. Open this list on ClinicalTrials.gov
- Ph1/Ph2NCT04908111 · A Trial of ChAdOx1 and MVA Vaccines Against MAGE-A3 and NY-ESO-1Cancer Research UK · suspended · Non-small Cell Lung Cancer (NSCLC), Squamous Oesophageal Cancer · principal investigator
- N/ANCT01818947 · Gefitinib Usage and Outcomes in Routine TreatmentAstraZeneca · completed · Lung Cancer · principal investigator
- Ph1NCT01809210 · Assess Safety & Efficacy of Selumetinib When Given in Combination With Standard First Line Treatment for Advanced Non-small Cell Lung CancerAstraZeneca · completed · Locally Advanced or Metastatic NSCL Cancer Stage IIIB IV · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 08:07 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 08:07 UTC. The ranking covers the 200 most relevant of 53 PubMed records, and a shared surname and initials can bring in a namesake. All 53 on PubMed
- Crizotinib versus chemotherapy in advanced ALK-positive lung cancer.N Engl J Med · 20132,837 citationsRCR 78.7
- First-line crizotinib versus chemotherapy in ALK-positive lung cancer.N Engl J Med · 20142,648 citationsRCR 76.2
- Tarlatamab for Patients with Previously Treated Small-Cell Lung Cancer.N Engl J Med · 2023529 citationsRCR 41.5
- 492 citationsRCR 16.0
- Osimertinib in Pretreated T790M-Positive Advanced Non-Small-Cell Lung Cancer: AURA Study Phase II Extension Component.J Clin Oncol · 2017486 citationsRCR 16.5
- Final Overall Survival Analysis From a Study Comparing First-Line Crizotinib Versus Chemotherapy in ALK-Mutation-Positive Non-Small-Cell Lung Cancer.J Clin Oncol · 2018325 citationsRCR 9.5
- Tarlatamab, a First-in-Class DLL3-Targeted Bispecific T-Cell Engager, in Recurrent Small-Cell Lung Cancer: An Open-Label, Phase I Study.J Clin Oncol · 2023312 citationsRCR 23.9
- 289 citationsRCR 7.7
- Efficacy and Safety of Rovalpituzumab Tesirine Compared With Topotecan as Second-Line Therapy in DLL3-High SCLC: Results From the Phase 3 TAHOE Study.J Thorac Oncol · 2021264 citationsRCR 13.5
- Vandetanib plus pemetrexed for the second-line treatment of advanced non-small-cell lung cancer: a randomized, double-blind phase III trial.J Clin Oncol · 2011248 citationsRCR 5.9